Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma

Blood

Volumn 106, Issue 9, 2005, Pages 3166-3174

  Piriou, Erwan ^b   Van Dort, Karel ^b   Nanlohy, Nening M ^b   Van Oers, Marinus H J ^b   Miedema, Frank ^b   Van Baarle, Debbie ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; B LYMPHOCYTE; CELL LOSS; CELLULAR IMMUNITY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE;

EID: 27644530601     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0432     Document Type: Article

References (63)

1. Miller G. Epstein-Barr virus: biology, pathogenesis and medical aspects. In: Fields BNKDM, ed. New York, NY: Raven Press; 1990:1921-1958.
2. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984;310:1225-1230.
3. Harty JT, Tvinnereim AR, White DW. CD8 T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 2000;18:275-308.
4. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
5. Pelicci PG, Knowles DM, Arlin ZA, et al. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders: implications for lymphomagenesis. J Exp Med. 1986;164:2049-2060.
6. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factor for non-Hodgkin's Lymphoma in people with AIDS. AIDS. 2000;14:133-140.
7. Kersten MJ, van Oers MHJ. AIDS-related non-Hodgkin's lymphomas. In: Schuitemaker H and Miedema F, eds. AIDS Pathogenesis. Dordrecht, the Netherlands: Kluwer Academic Publishers; 2000:177-194.
8. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol. 2000;27:390-401.
9. Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon, France, 17-24 June 1997. IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492.
10. Shibata D, Weiss LM, Hernandez AM, et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;81:2102-2109.
11. Kersten MJ, Van Gorp J, Pals ST, Boon F, Van Oers MHJ. Expression of Epstein-Barr virus latent genes and adhesion molecules in AIDS related non-Hodgkin's lymphomas: correlation with histology and CD4-cell number. Leuk Lymphoma. 1998;30:515-524.
12. Kersten MJ, Klein MR, Holwerda AM, Miedema F, Van Oers MHJ. EBV-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest. 1997;99:1525-1533.
13. Dalod M, Dupuis M, Deschemin JC, et al. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8() responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol. 1999;73:7108-7116.
14. van Baarle D, Hovenkamp E, Callan MFC, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin's lymphoma. Blood. 2001;98:146-155.
15. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
16. McNeil AC, Shupert WL, Iyasere CA, et al. Highlevel HIV-1 viremia suppresses viral antigenspecific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A. 2001;98:13878-13883.
17. + T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002;76:12584-12595.
18. Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003;101:2686-2692.
19. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
20. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856.
21. Kaech SM, Ahmed R. Immunology: CD8 T cells remember with a little help. Science. 2003;300:263-265.
22. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056-8063.
23. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-2213.
24. Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of the CD8+ T cell-mediated control of a g-herpesvirus in the absence of CD4+ T cells. J Exp Med. 1996;184:863-871.
25. + T cells during long-term gammaherpesvirus infection. J Virol. 2001;75:7744-7748.
26. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistance and immune evasion in the absence of memory T cell help. Science. 2003;302:659-662.
27. + T-helper responses. J Virol. 2001;75:8649-8659.
28. Precopio ML, Sullivan JL, Willard C, Somasundaran M, Luzuriaga K. Differential kinetics and specificity of EBV-specific CD4(+) and CD8(+) T cells during primary infection. J Immunol. 2003;170:2590-2598.
29. Amyes E, Hatton C, Montamat-Sicotte D, et al. Characterization of the CD4+ T cell responses to Epstein-Barr virus during primary and persistent infection. J Exp Med. 2003;198:903-911.
30. Münz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000;191:1649-1660.
31. Steven NM, Annels NE, Kumar A, et al. Immediate early and early lytic cycle proteins are frequent targets for the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997;185:1605-1617.
32. Saulquin X, Ibisch C, Peyrat MA, et al. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur J Immunol. 2000;30:2531-2539.
33. + T-cell response in untreated HIV-infected subjects. Eur J Immunol. 2005;35:796-805.
34. + T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med. 2004;10:406-410.
35. Kostense S, Ogg GS, Manting EH, et al. High viral burden in the presence of major HIV-specific CD8+ T cell expansions: evidence for impaired T cell effector function. Eur J Immunol. 2001;31:677-686.
36. + memory T cell activation requirements at the single clonotype level. J Immunol. 2002;169:1207-1218.
37. Schellekens PT, Roos MT, De Wolf F, Lange JM, Miedema F. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J Clin Immunol. 1990;10:121-127.
38. Niesters HGM, van Esser J, Fries E, et al. The development of a high-throughput real-time quantitative assay for Epstein-Barr virus detection. J Clin Microbiol. 2000;38:712-715.
39. van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis. 2002;186:405-409.
40. Cameron KR, Stamminger T, Craxton M, et al. The 160,000-Mr virion protein encoded at the right end of the herpesvirus saimiri genome is homologous to the 140,000-Mr membrane antigen encoded at the left end of the Epstein-Barr virus genome. J Virol. 1987;61:2063-2070.
41. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia. 1998;12:2006-2014.
42. Piriou E, van Dort K, Nanlohy NM, et al. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol. 2004;172:6931-6937.
43. Younes SA, Yassine-Diab B, Dumont AR, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med. 2003;198:1909-1922.
44. + T cells after clearance of hepatitis C virus. J Immunol. 2002;169:2210-2214.
45. Bourgeois C, Veiga-Fernandes H, Joret AM, Rocha B, Tanchot C. CD8 lethargy in the absence of CD4 help. Eur J Immunol. 2002;32:2199-2207.
46. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.
47. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol. 2004;5:927-933.
48. Torre-Cisneros J, Roman J, Torres A, et al. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation. J Infect Dis. 2004;190:1596-1599.
49. Khanna R, Burrows SR, Thomson SA, et al. Class I processing defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol. 1997;158:3619-3625.
50. + T cells specific for an MHC class II promiscuous epitope. J Immunol. 2002;169:2172-2179.
51. Paludan C, Bickham K, Nikiforow S, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol. 2002;169:1593-1603.
52. +-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol. 2003;77:12088-12104.
53. Voo KS, Fu T, Heslop HE, et al. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002;62:7195-7199.
54. Landais E, Saulquin X, Scotet E, et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood. 2004;103:1408-1416.
55. + T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest. 2004;114:542-550.
56. Lee SP, Brooks JM, Al-Jarrah H, et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med. 2004;199:1409-1420.
57. + T lymphocytes. J Exp Med. 2004;199:459-470.
58. Munz C. Epstein-Barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med. 2004;199:1301-1304.
59. Blake N, Lee S, Redchenko I, et al. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala) containing protein requires exogenous processing. Immunity. 1998;7:791-801.
60. Hislop AD, Gudgeon NH, Callan MFC, et al. EBVspecific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol. 2001;167:2019-2029.
61. Quesnel A, Pozzetto B, Touraine F, et al. Antibodies to Epstein-Barr virus and cytomegalovirus in relation to CD4 cell number in human immunodeficiency virus 1 infection. J Med Virol. 1992;36:60-64.
62. Stevens SJ, Blank BS, Smits PH, Meenhorst PL, Middeldorp JM. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS. 2002;16:993-1001.
63. Martinez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol. 2002;14:528-532.